At steady state, empagliflozin concentration–time profiles showed a trend similar to single dose profiles on day 1 (Fig. 1 ) [note, 2 patients (1 each from the 10 mg and 100 mg dose groups on day 9) were excluded due to incomplete data or low exposure].
← all excerpts
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
1
—
—